Quick Answer
Akari Therapeutics Plc reported R&D Expense of $2.81 million for fiscal year 2025.
Akari Therapeutics Plc R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $2.81M | -59.7% |
| 2024 | $6.98M | +28.1% |
| 2023 | $5.45M | -43.0% |
| 2022 | $9.56M | +4.7% |
| 2021 | $9.13M | +3.6% |
| 2020 | $8.82M | +0.9% |
| 2019 | $8.74M | -25.9% |
| 2018 | $11.80M | -49.3% |
| 2017 | $23.29M | +34.6% |
| 2016 | $17.31M | +198.4% |
| 2015 | $5.80M | +258.8% |
| 2014 | $1.62M | +26.7% |
| 2013 | $1.28M | -14.0% |
| 2012 | $1.48M | +76.3% |
| 2011 | $841.0K | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $249.0K | +74.1% | -62.7% |
| June 30, 2025 | $667.0K | -79.9% | -18.0% |
| March 31, 2025 | $813.0K | -64.3% | +468.5% |
| September 30, 2024 | $143.0K | +145.5% | -95.7% |
| June 30, 2024 | $3.31M | +117.5% | +45.4% |
| March 31, 2024 | $2.28M | +31.7% | +825.8% |
| September 30, 2023 | -$314.0K | — | -120.6% |
| June 30, 2023 | $1.52M | — | -12.0% |
- Akari Therapeutics Plc showed a decrease of -59.7% in R&D Expense compared to the prior fiscal year.
- Over the 2011–2025 period, Akari Therapeutics Plc’s r&d expense has grown by 234.7% (from $841.0 thousand to $2.81 million).
- The most recent figure is from Akari Therapeutics Plc’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: